Skip main navigation

Corporate NewsDrug Discovery

REPROCELL’s Corporate News


New collaboration at Hartree National Centre for Digital Innovation combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in artificial intelligence and machine learning.

Read more →

Glasgow UK - 17 August 2022: A drug being developed for the treatment of severe asthma and COPD has passed an important milestone. Scientists at REPROCELL compared the effects of the compound, RCD405, with drugs that are currently used to treat respiratory disease by assessing the effects of the drug ex vivo in human living bronchi.

Read more →

Next month, the Safety Pharmacology Society (SPS) will be hosting its first in-person meeting since 2019. Now in its 22nd year, this dynamic forum is known for its global networking opportunities and events promoting the best practices in safety pharmacology.

Read more →

Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision medicine strategies.

Read more →

Glasgow UK - 21 January 2022: REPROCELL has published an article highlighting the power of human biospecimens in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled Dynamizing Biomarker R&D with Smarter Biospecimens, explains why quality biospecimens are essential to translational biomarker research.

Read more →

GLASGOW, October 25, 2021: Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn’s disease tissues will be used to investigate the therapeutic potential of Hoth's HT-003 drugs. All testing will be performed at REPROCELL's Centre for Predictive Drug Discovery.

Read more →

Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR).

Read more →

NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh explants of ulcerative colitis and Crohn’s disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases. All testing will be performed by REPROCELL.  

Read more →